Demotensin 5 and 6 in the NTS1-R-targeted imaging of tumours: Synthesis and preclinical results

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 34, Issue 11, 2007, Pages 1804-1814

  Maina, Theodosia ^a   Nikolopoulou, Anastasia ^a   Stathopoulou, Eleni ^a   Galanis, Athanassios S ^b   Cordopatis, Paul ^b   Nock, Berthold A ^a  

^a INSTITUTE OF NANOSCIENCE AND NANOTECHNOLOGY   (Greece)

^b UNIVERSITY OF PATRAS   (Greece)

Author keywords

Diagnostic tumour imaging; NTS1 R targeted imaging; Tetraamine neurotensin

Indexed keywords

DEMOTENSIN 5 TECHNETIUM 99M; DEMOTENSIN 6 TECHNETIUM 99M; NEUROTENSIN DERIVATIVE; NEUROTENSIN SUBTYPE 1 RECEPTOR; TECHNETIUM 99M; TRACER; UNCLASSIFIED DRUG; DIAGNOSTIC AGENT; NEUROTENSIN; NEUROTENSIN RECEPTOR; NEUROTENSIN TYPE 1 RECEPTOR; RADIOPHARMACEUTICAL AGENT; TECHNETIUM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CANCER GRAFT; COLON CANCER; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG SYNTHESIS; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IMAGING SYSTEM; INCUBATION TIME; ISOTOPE LABELING; MALE; MOUSE; NONHUMAN; RADIOCHEMISTRY; URINARY EXCRETION; XENOGRAFT; ANIMAL; ANTIBODY SPECIFICITY; CHEMISTRY; COLORECTAL TUMOR; DRUG DELIVERY SYSTEM; METABOLIC CLEARANCE RATE; METABOLISM; METHODOLOGY; SCINTISCANNING; SYNTHESIS; TISSUE DISTRIBUTION; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; DRUG DELIVERY SYSTEMS; HUMANS; MALE; METABOLIC CLEARANCE RATE; MICE; NEUROTENSIN; ORGAN SPECIFICITY; RADIOPHARMACEUTICALS; RECEPTORS, NEUROTENSIN; TECHNETIUM; TISSUE DISTRIBUTION;

EID: 35349001224     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-007-0489-z     Document Type: Article

References (33)

1. Reubi JC. Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr Rev 2003;24:389-427.
2. Reubi JC, Mäcke HR, Krenning EP. Candidates for peptide receptor radiotherapy today and in the future. J Nucl Med 2005;46(Suppl 1):67S-75S.
3. Kwekkeboom DJ, Krenning EP. Somatostatin receptor imaging. Semin Nucl Med 2002;32:84-91.
4. Breeman WAP, de Jong M, Kwekkeboom DJ, Valkema R, Bakker WH, Kooij PPM, et al. Somatostatin receptor-mediated imaging and therapy: basic science, current knowledge, limitations and future perspectives. Eur J Nucl Med Mol Imaging 2001;28:1421-9.
5. Reubi JC, Horisberger U, Essed CE, Jeekel J, Klijn JG, Lamberts SW. Absence of somatostatin receptors in human exocrine pancreatic adenocarcinomas. Gastroenterology 1988;95:760-3.
6. 2 somatostatin receptor gene expression in human pancreatic and colorectal cancer. Cancer Res 1996;56:1823-7.
7. Vincent JP, Mazella J, Kitabgi P. Neurotensin and neurotensin receptors. Trends Pharmacol Sci 1999;20:302-9.
8. Reubi JC, Waser B, Friess H, Buchler M, Laissue J. Neurotensin receptors: a new marker for human ductal pancreatic adenocarcinoma. Gut 1998;42:546-50.
9. Wang L, Friess H, Zhu Z, Graber H, Zimmermann A, Korc M, et al. Neurotensin receptor-1 mRNA analysis in normal pancreas and pancreatic disease. Clin Cancer Res 2000;6:566-71.
10. Ehlers RA, Kim S, Zhang Y, Ethridge RT, Murrilo C, Hellmich MR, et al. Gut peptide receptor expression in human pancreatic cancers. Ann Surg 2000;231:838-48.
11. Ishizuka J, Townsend CM, Thomson JC. Neurotensin regulates growth of human pancreatic cancer. Ann Surg 1993;217:439-46.
12. Reubi JC, Waser B, Schaer JC, Laissue JA. Neurotensin receptors in human neoplasms: high incidence in Ewing's sarcomas. Int J Cancer 1999;82:213-8.
13. Maoret JJ, Pospaï D, Rouyer-Fessard C, Couvineau A, Laboisse C, Voisin T, et al. Neurotensin receptor and its mRNA are expressed in many human colon cancer cell lines but not in normal colonic epithelium: binding studies and RT-PCR experiments. Biochem Biophys Res Commun 1994;203:465-71.
14. Rettenbacher M, Reubi JC. Localization and characterization of neuropeptide receptors in human colon. Naunyn-Schmiedebergs Arch Pharmacol 2001;364:291-304.
15. Reubi JC, Waser B, Schmassmann A, Laissue JA. Receptor autoradiographic evaluation of cholecystokinin, neurotensin, somatostatin and vasoactive intestinal peptide receptors in gastrointestinal adenocarcinoma samples: where are they really located? Int J Cancer 1999;81:376-386.
16. Achilefu S, Srinivasan A, Schmidt MA, Jimenez HN, Bugaj JE, Erion JL. Novel bioactive and stable neurotensin peptide analogues capable of delivering radiopharmaceuticals and molecular beacons to tumors. J Med Chem 2003;46:3403-11.
17. 111In-labelled DTPA- and DOTA-conjugated neurotensin analogues for imaging and therapy of exocrine pancreatic cancer. Eur J Nucl Med Mol Imaging 2003;30:1134-9.
18. Schubiger PA, Allemann-Tannahill L, Egli A, Schibli R, Alberto R, Carrel-Rémy N, et al. Catabolism of neurotensins. Implications for the design of radiolabeling strategies of peptides. Q J Nucl Med 1999;43:155-8.
19. García-Garayoa E, Allemann-Tannahill L, Bläuenstein P, Willmann M, Carrel-Rémy N, Tourwé D, et al. In vitro and in vivo evaluation of new radiolabeled neurotensin(8-13) analogues with high affinity for NT1 receptors. Nucl Med Biol 2001;28:75-84.
20. Brühlmeier M, García-Garayoa E, Blanc A, Holzer B, Gergely S, Tourwé D, et al. Stabilization of neurotensin analogues: effect on peptide catabolism, biodistribution and tumor binding. Nucl Med Biol 2002;29:321-7.
21. 99mTc. J Nucl Med 2002;43:374-83.
22. 99mTc-labeled neurotensin analogues with optimized biodistribution properties. J Med Chem 2006;49:1833-6.
23. Kitabgi P, De Nadai F, Rovère, Bidard JN. Biosynthesis, maturation, release and degradation of neurotensin and neuromedin N. Ann N Y Acad Sci 1992;668:30-42.
24. Davis TP, Konings PN. Peptidases in the CNS: formation of biologically active, receptor-specific peptide fragments. Crit Rev Neurobiol 1993;7:163-74.
25. Doulut S, Rodriguez M, Lugrin D, Vecchini F, Kitabgi P, Aumelas A, et al. Reduced peptide bond pseudopeptide analogues of neurotensin. Peptide Res 1992;5:30-8.
26. 2NH) pseudopeptide analogues of the C-terminal hexapeptide of neurotensin. Int J Pept Res 1993;41:181-4.
27. 99mTc-NT-XI, evaluated in ductal pancreatic adenocarcinoma patients. J Nucl Med 2003;44:1649-54.
28. 99mTc. J Med Chem 2006;49:4767-76.
29. Cusack B, McCormick DJ, Pang YP, Souder T, Garcia R, Fauq A, et al. Pharmacological and biochemical profiles of unique neurotensin 8-13 analogs exhibiting species selectivity, stereoselectivity, and superagonism. J Biol Chem 1995;270(31/4):18359-66.
30. Bidard JN, de Nadai F, Rovère F, Moinier D, Laur, J, Martinez J, et al. Immunological and biochemical characterization of processing products from the neurotensin/neuromedin N precursor in the rat medullary thyroid carcinoma 6-23 cell line. Biochem J 1993;291:225-33.
31. Bläuenstein P, Pfeiffer G, Schubiger PA, Anderegg G, Zollinger K, May K, et al. Chemical and biological properties of a cationic Tc-tetraamine complex. Int J Appl Radiat Isot 1985;36:315-7.
32. Mantegazzi D, Ianoz E, Lerch P, Nicolò F, Chapuis G. Preparation and crystal structure of polymeric lithium[dioxo-Tc(V)-tetraazaundecane] bis(trifluoromethanesulfonate) complex. Inorg Chim Acta 1990;176:99-105.
33. +. Inorg Chem 1988;27:4127-30.